Fax: (612) 626-1441
Differential gene expression in leiomyosarcoma
Article first published online: 31 JUL 2003
Copyright © 2003 American Cancer Society
Volume 98, Issue 5, pages 1029–1038, 1 September 2003
How to Cite
Skubitz, K. M. and Skubitz, A. P. N. (2003), Differential gene expression in leiomyosarcoma. Cancer, 98: 1029–1038. doi: 10.1002/cncr.11586
- Issue published online: 20 AUG 2003
- Article first published online: 31 JUL 2003
- Manuscript Accepted: 16 MAY 2003
- Manuscript Revised: 22 APR 2003
- Manuscript Received: 29 JAN 2003
- gene expression;
- leiomyosarcoma (LMS);
- calpain 6;
- proteolipid 1;
- pituitary tumor transforming;
- cyclin-dependent kinase inhibitor 2A;
- protein regulator of cytokinesis;
Leiomyosarcomas (LMS) are a common subtype of soft tissue sarcoma. The molecular causes of the disease remain unclear.
In the current study, gene expression in LMS, leiomyomas, and normal myometrium was examined. RNA was prepared and gene expression was determined using microarray analysis arrays containing approximately 12,000 known genes and 48,000 expressed squence tags (ESTs).
A number of genes were found to be differentially expressed in these sample sets, and six genes including cyclin-dependent kinase inhibitor 2A, diaphanous (Drosophila homolog) 3, doublecortin, calpain 6, interleukin-17B, and proteolipid 1 were found to be overexpressed in LMS compared with normal myometrium and 18 other tissues. Sets of genes were identified whose expression could be used to cluster samples with either LMS, leiomyomas, or normal myometrium.
The authors concluded that differences in gene expression can be detected between LMS and leiomyomas, normal myometrium, and other tissues, and that these changes in gene expression may yield clues with regard to the pathophysiology of leiomyosarcoma. Cancer 2003;98:1029–38. © 2003 American Cancer Society.